RecruitingNot ApplicableNCT05794464
The SAFE Prospective Registry
Secretoneurin as a Biomarker of Atrial Fibrillation rEcurrence After Catheter Ablation/Electrical Cardioversion
Sponsor
University Hospital Ostrava
Enrollment
60 participants
Start Date
May 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Secretoneurin (SN) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. SN suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. SN is a novel biomarker that has shown the potential to predict adverse arrhythmic events.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Atrial fibrillation (Afib); (paroxysmal, persistent)
- Patients indicated for catheter ablation and/or electrical cardioversion
- Signed informed consent
Exclusion Criteria8
- Longstanding or permanent atrial fibrillation
- Severe mitral regurgitation
- Heart failure with a permanently reduced ejection fraction
- Cerebral ischaemic stroke in \< 3 months
- Severe kidney injury
- Severe renal insufficiency
- Hepatic insufficiency limiting biomarker sampling
- Myocardial infarction \< 3 months
Interventions
PROCEDURECatheter ablation and/or electrical cardioversion
Catheter ablation and/or electrical cardio version are procedures intended to treat atrial fibrillation.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05794464